#Codagenix #VaxThera #Yellow Fever

VaxThera and Codagenix Join Forces for a Revolutionary Yellow Fever Vaccine

In a significant move towards enhancing public health, VaxThera S.A.S., a Colombian biotech firm, has formed a partnership with Codagenix Inc. This collaboration aims to propel the development of a pioneering yellow fever vaccine named Syn17D-YF. This fully synthetic vaccine candidate is poised to redefine vaccine manufacturing with its state-of-the-art methodologies.

Modernizing Vaccine Production

yellow fever vaccines have long served as crucial public health tools globally, yet they are typically produced using traditional methods involving embryonated chicken eggs—an outdated technique that poses challenges in times of increased demand due to outbreaks. VaxThera recognizes the pressing need for a modern alternative.

The innovative Syn17D-YF, created through Codagenix's proprietary synthetic biology technology, is derived from the yellow fever virus genome sequence of the 17D-204 strain. Its genetic stability and high-yield production capabilities in cell culture mark a major improvement over conventional vaccines, ensuring both safety and efficacy without the risks of mutations encountered in older production methods.

Professor Jorge Osório, CEO of VaxThera, emphasizes the historical significance of yellow fever in Latin America and insists that vaccine shortages must not dictate the future health of the region. By leveraging their expertise and manufacturing capabilities, VaxThera is determined to make a global impact.

A Bright Future for Global Vaccination Strategies

Established just five years ago, VaxThera has created a biotechnology ecosystem in Medellín, Colombia, equipped for research, development, and manufacturing. With the capability to produce over 150 million vaccine doses annually, the facility adheres to international Good Manufacturing Practices (GMP), setting the stage for a robust response to the demands of the global market.

Dr. Jeffrey Fu, Codagenix's Chief Business Officer, articulates that Syn17D-YF addresses the need to modernize yellow fever vaccination, and VaxThera possesses the strategic vision and infrastructure to help realize its potential impact on a worldwide scale.

Addressing Global Health Challenges

The urgency for such innovative solutions is underscored by recent alerts from the World Health Organization regarding yellow fever outbreaks in both endemic and non-endemic regions. With a focus on increasing vaccine accessibility and effectiveness, the collaboration between VaxThera and Codagenix aims to alleviate supply chain challenges often linked to current yellow fever vaccines.

Both companies are committed to contributing significantly to the World Health Organization's initiative,